Lori J. Wirth

Harvard University — United States

Medicine · Health Sciences

67h-index19.4kcitations566works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Thyroid Cancer Diagnosis and Treatment(183), Head and Neck Cancer Studies(125), Lung Cancer Treatments and Mutations(83), Cancer Immunotherapy and Biomarkers(43), Salivary Gland Tumors Diagnosis and Treatment(41)

Publications565 total

Who Benefits and When? Applying Circulating Tumor Human Papillomavirus DNA for Human Papillomavirus–Associated Oropharyngeal Carcinoma
JCO Oncology Practice·2026
Supplementary_Table1 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
2025Open Access
Supplementary_Table3 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
2025Open Access
Supplementary_Table4 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
2025Open Access
Supplementary_Table5 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
2025Open Access
Supplementary_Table2 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
2025Open Access
Supplementary Figures S1-S7 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
2025Open Access
Alcohol and Cancer
JAMA·2025
Radiomic Artificial Intelligence Models Predicting the Response of Colorectal Cancer Liver Metastases to Chemotherapy—A Systematic Review
ANZ Journal of Surgery·2025Open Access
Clinical validation of an HPV whole genome sequencing assay for molecular residual disease detection in HPV-associated head and neck cancer patients treated with surgery
2025Open Access
280 Cell atlas-resolved discovery and targeting of novel CAR antigens in anaplastic thyroid carcinoma
Regular and Young Investigator Award Abstracts·2025Open Access
548 A Phase 1/2 study of a first-in-class non-cellular antibody-drug conjugate, micvotabart pelidotin (micvo), in combination with pembrolizumab in advanced head & neck squamous cell carcinoma (HNSCC)
Regular and Young Investigator Award Abstracts·2025Open Access
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i> -Mutant Medullary Thyroid Cancer
Thyroid·2025· 2 citedOpen Access
Emerging EGFR-Targeted Therapy in Head and Neck Cancer
JAMA Oncology·2025· 5 cited
Artificial Intelligence‐Derived Intramuscular Adipose Tissue Assessment Predicts Perineal Wound Complications Following Abdominoperineal Resection
World Journal of Surgery·2025Open Access
1025eTiP A phase I/II study of a first-in-class non-cellular antibody-drug conjugate, micvotabart pelidotin (MICVO), in combination with pembrolizumab in select advanced solid tumors
Annals of Oncology·2025Open Access
Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer
npj Precision Oncology·2025· 5 citedOpen Access
Data from Direct Comparison of Alternative Blood-Based Approaches for Early Detection and Diagnosis of HPV-Associated Head and Neck Cancers
2025Open Access
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
Thyroid·2025· 168 cited
NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025
Journal of the National Comprehensive Cancer Network·2025· 11 cited
page 1 of 29Next →

Frequent Co-authors

Robert I. Haddad(14), Marcia S. Brose(12), Steven I. Sherman(12), Martin Schlumberger(9), Maria E. Cabanillas(9), Bruce Robinson(8), Manisha H. Shah(8), Douglas W. Ball(6), Eric J. Sherman(6), Naifa L. Busaidy(6), John A. Ridge(6), Matthew D. Ringel(6), Peter M. Sadow(6), Makoto Tahara(5), Rossella Elisei(5), Matthew H. Taylor(5), Lisa Licitra(5), Vivek Subbiah(5), Hormoz Ehya(5), Megan R. Haymart(5)